The Predictive Value of CHA2DS2-VASc Score on Major Adverse Cardiovascular Events in Patients with Three Vessels or Left Main Diseases of Coronary Heart Disease

doi:10.12114/j.issn.1007-9572.2023.0109

Abstract

Abstract:

Background

SYNTAX score is the most common system for predicting the prognosis of patients with coronary heart disease based on coronary anatomy and lesions, and an evaluation method based on general clinical data is needed to improve the effectiveness of prediction.

Objective

To investigate the relationship between CHA₂DS₂-VASc scores and major adverse cardiovascular events in patients with three-vessel disease (TVD) or left main coronary artery disease (LMD) .

Methods

A total of 630 TVD/LMD patients were enrolled, and 276 patients were divided into the mild lesion group (0—22 points), 249 cases in the moderate lesion group (23—32 points) and 105 cases in the severe lesion group (≥33 points) according to SYNTAX score. Pearson correlation analysis and partial correlation analysis were used to explore the correlation between quantitative data, and univariate and multivariate Logistic regression analysis were used to investigate whether CHA₂DS₂-VASc and SYNTAX scores were risk factors for the incidence of MACEs within 3 years. The receiver operating characteristic (ROC) curve was plotted to evaluate the CHA₂DS₂-VASc score in predicting the occurrence of MACEs within 3 years. The ROC curves for predicting MACEs of CHA₂DS₂-VASc score, SYNTAX score, and the combination of the two scoring systems were compared using the Delong method.

Results

There were statistically significant differences in age, congestive heart failure, eGFR, LVEF, SYNTAX score, CHA₂DS₂-VASc score, MACEs within 3 years, death and non-fatal myocardial infarction among the groups with diferent degree of coronary stenosis (P<0.05), and CHA₂DS₂-VASc score was positively correlated with SYNTAX score (r=0.109, P=0.003). Multivariate Logistic regression analysis showed that hypertension〔OR=1.753, 95%CI (1.047, 2.938) 〕, LVEF 〔OR=0.962, 95%CI (0.942, 0.982) 〕, SYNTAX score 〔OR=1.028, 95%CI (1.002, 1.055) 〕, and CHA₂DS₂-VASc score 〔OR=1.210, 95%CI (1.070, 1.369) 〕 were independent influencing factors of MACEs of TVD/LMD patients within 3 years (P<0.05). ROC curve analysis showed that AUC of SYNTAX score predicting MACEs is 0.638, and AUC of CHA₂DS₂-VASc score predicting MACEs is 0.619. The AUC of combined SYNTAX and CHA₂DS₂-VASc score predicting MACEs was 0.685. The AUC difference between SYNTAX and CHA₂DS₂-VASc score was 0.019 (P=0.587) by Delong method, indicating that both SYNTAX and CHA₂DS₂-VASc scores had a predictive effect on MACEs, but the AUC difference was not statistically significant. The AUC difference between the combined two kind of score and SYNTAX score alone was 0.046 9 (P=0.046), and the AUC difference between the combined two kind of scores and CHA₂DS₂-VASc score oalone was 0.065 9 (P=0.043) .

Conclusion

The CHA₂DS₂-VASc score can be used to predict coronary artery severity and MACEs within 3 years in patients with three-vessel disease/left main coronary artery disease. Combined CHA₂DS₂-VASc and SYNTAX scoring system can effectively improved the predictive value of MACEs within 3 years.

Key words: Coronary artery disease, CHA₂DS₂-VASc score, SYNTAX score, Triple-vessel diseases, Left main disease, Predictive value

摘要：

背景

SYNTAX评分是基于冠状动脉解剖结构和病变情况，预测冠心病患者预后常用的评分系统之一，但临床上需要一种基于一般临床资料的评估方法，以提高其预测效力。

目的

探讨CHA₂DS₂-VASc卒中风险评分在冠心病三支血管病变（TVD）或左主干病变（LMD）患者中与主要不良心血管事件（MACEs）之间的关系。

方法

本研究共纳入2009年1月—2014年5月在首都医科大学附属北京友谊医院接受经皮冠状动脉介入治疗（PCI）的630例TVD/LMD患者，根据SYNTAX评分分为轻度病变组（0~22分）276例、中度病变组（23~32分）249例和重度病变组（≥33分）105例。采用Pearson相关性分析及偏相关分析探究定量资料之间的相关性，采用单因素及多因素Logistic回归分析探究CHA₂DS₂-VASc和SYNTAX评分是否为TVD/LMD患者3年内发生MACEs的危险因素。绘制受试者工作特征（ROC）曲线评价CHA₂DS₂-VASc评分预测3年内发生MACE的效能。使用Delong方法对CHA₂DS₂-VASc评分、SYNTAX评分以及两评分系统联合预测MACEs的ROC曲线进行比较。

结果

不同SYNTAX评分组在年龄、合并充血性心力衰竭、估算肾小球滤过率（eGFR）、左心室射血分数（LVEF）、SYNTAX评分、CHA₂DS₂-VASc评分、3年内MACEs、死亡和非致死性心肌梗死比较，差异有统计学意义（P<0.05），CHA₂DS₂-VASc评分与SYNTAX评分呈正相关（r=0.109，P=0.003）。多因素Logistic回归分析结果显示，高血压〔OR=1.753，95%CI（1.047，2.938）〕、LVEF〔OR=0.962，95%CI（0.942，0.982）〕、SYNTAX评分〔OR=1.028，95%CI（1.002，1.055）〕及CHA₂DS₂-VASc评分〔OR=1.210，95%CI（1.070，1.369）〕升高是TVD/LMD患者3年内发生MACEs的独立影响因素（P<0.05）。ROC曲线分析结果显示，SYNTAX评分预测MACEs的ROC曲线下面积（AUC）是0.638，CHA₂DS₂-VASc评分预测MACEs的AUC是0.619。联合应用SYNTAX评分及CHA₂DS₂-VASc评分预测MACEs的AUC是0.685。使用Delong方法进行头对头比较发现，SYNTAX与CHA₂DS₂-VASc评分预测MACEs的AUC差值为0.019（P=0.587），提示SYNTAX与CHA₂DS₂-VASc评分都具有对MACEs的预测效果，但其AUC差值无统计学意义。联合应用SYNTAX评分和CHA₂DS₂-VASc评分预测MACEs与SYNTAX评分单独预测MACEs的AUC差值为0.046 9（P=0.046），与CHA₂DS₂-VASc评分单独预测MACE的AUC差值为0.065 9（P=0.043），差异均有统计学意义。

结论

CHA₂DS₂-VASc评分系统可用于预测TVD/LMD患者冠状动脉病变的严重程度及3年内MACE的发生情况，联合CHA₂DS₂-VASc与SYNTAX评分系统，可有效提高对3年MACEs的预测价值。

关键词: 冠心病, CHA₂DS₂-VASc评分, SYNTAX评分, 三支血管病变, 左主干病变, 预测价值

WANG Qiushi,LI Hongwei. The Predictive Value of CHA₂DS₂-VASc Score on Major Adverse Cardiovascular Events in Patients with Three Vessels or Left Main Diseases of Coronary Heart Disease[J]. Chinese General Practice, 2023, 26(33): 4130-4136. DOI: 10.12114/j.issn.1007-9572.2023.0109.
王秋实,李虹伟. CHA₂DS₂-VASc卒中风险评分对冠心病三支血管或左主干病变患者主要不良心血管事件的预测价值研究[J]. 中国全科医学, 2023, 26(33): 4130-4136. DOI: 10.12114/j.issn.1007-9572.2023.0109.

Figures/Tables 6

References 21

[1]	PIEPOLI M F, HOES A W, AGEWALL S，et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice：the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice （constituted by representatives of 10 societies and by invited experts）Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation （EACPR）[J]. Eur Heart J，2016,37(29):2315-2381. DOI：10.1093/eurheartj/ehw106.
[2]	COLLET J P, THIELE H, BARBATO E，et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J，2021,42(14):1289-1367. DOI：10.1093/eurheartj/ehaa575.
[3]	ZHANG X N, LV X, LI X D，et al. Dysregulated circulating SOCS3 and haptoglobin expression associated with stable coronary artery disease and acute coronary syndrome：an integrated study based on bioinformatics analysis and case-control validation[J]. Anatol J Cardiol，2020,24(3):160-174. DOI：10.14744/AnatolJCardiol.2020.56346.
[4]	KAWASHIMA H, TAKAHASHI K, ONO M，et al. Mortality 10 years after percutaneous or surgical revascularization in patients with total coronary artery occlusions[J]. J Am Coll Cardiol，2021,77(5):529-540. DOI：10.1016/j.jacc.2020.11.055.
[5]	MOHR F W, MORICE M C, KAPPETEIN A P，et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease：5-year follow-up of the randomised，clinical SYNTAX trial[J]. Lancet，2013,381(9867):629-638. DOI：10.1016/S0140-6736(13)60141-5.
[6]	KUMBHANI D J, ANNON C P, BEAVERS C J，et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease：a report of the American college of cardiology solution set oversight committee[J]. J Am Coll Cardiol，2021,77(5):629-658. DOI：10.1016/j.jacc.2020.09.011.
[7]	CHICHAREON P, VAN KLAVEREN D, MODOLO R，et al. Predicting 2-year all-cause mortality after contemporary PCI：updating the logistic clinical SYNTAX score[J]. Catheter Cardiovasc Interv，2021,98(7):1287-1297. DOI：10.1002/ccd.29490.
[8]	CAMPOS C M, STANETIC B M, FAROOQ V，et al. Risk stratification in 3-vessel coronary artery disease：applying the SYNTAX ScoreⅡin the Heart Team Discussion of the SYNTAX Ⅱtrial[J]. Catheter Cardiovasc Interv，2015,86(6):E229-238. DOI: 10.1002/ccd.25907.
[9]	FAUCHIER L, LECOQ C, ANCEDY Y，et al. Evaluation of 5 prognostic scores for prediction of stroke，thromboembolic and coronary events，all-cause mortality，and major adverse cardiac events in patients with atrial fibrillation and coronary stenting[J]. Am J Cardiol，2016,118(5):700-707. DOI：10.1016/j.amjcard.2016.06.018.
[10]	AKBOĞA M K, YıLMAZ S, YALÇıN R. Prognostic value of CHA₂DS₂-VASc score in predicting high SYNTAX score and in-hospital mortality for non-ST elevation myocardial infarction in patients without atrial fibrillation[J]. Anatol J Cardiol，2021,25(11):789-795. DOI：10.5152/AnatolJCardiol.2021.03982.
[11]	Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. 2019 Chinese Society of Cardiology （CSC） guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction[J]. Chinese Journal of Cardiology，2019,47(10):766-783. DOI: 10.3760/cma.j.issn.0253-3758.2019.10.003.
[12]	WEIRICK T. Percutaneous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease[J]. Curr Cardio Risk Rep，2009,3(5):309-310. DOI: 10.1007/s12170-009-0055-2.
[13]	CAPODANNO D, DI SALVO M E, CINCOTTA G，et al. Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease[J]. Circ Cardiovasc Interv，2009,2(4):302-308. DOI：10.1161/CIRCINTERVENTIONS.108.847137.
[14]	PALMERINI T, GENEREUX P, CAIXETA A，et al. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY （Acute Catheterization and Urgent Intervention Triage StrategY） trial[J]. J Am Coll Cardiol，2011,57(24):2389-2397. DOI：10.1016/j.jacc.2011.02.032.
[15]	WYKRZYKOWSKA J J, GARG S, GIRASIS C，et al. Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS （Limus Eluted from A Durable versus ERodable Stent coating） trial[J]. J Am Coll Cardiol，2010,56(4):272-277. DOI：10.1016/j.jacc.2010.03.044.
[16]	LIP G Y, LIN H J, CHIEN K L，et al. Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke，in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study[J]. Int J Cardiol，2013,168(1):414-419. DOI：10.1016/j.ijcard.2012.09.148.
[17]	FUNABASHI N, UEHARA M, TAKAOKA H，et al. The CHA₂DS₂-VASc score predicts 320-slice CT-based coronary artery plaques and >50% stenosis in subjects with chronic and paroxysmal atrial fibrillation[J]. Int J Cardiol，2014,172(1):e234-237. DOI：10.1016/j.ijcard.2013.12.148.
[18]	FORD E S, GILES W H, MOKDAD A H. The distribution of 10-Year risk for coronary heart disease among US adults：findings from the National Health and Nutrition Examination SurveyⅢ[J]. J Am Coll Cardiol，2004,43(10):1791-1796. DOI：10.1016/j.jacc.2003.11.061.
[19]	EBERLY L E, NEATON J D, Thomas A J, et al. Multiple Risk Factor Intervention Trial[J]. Clin Trials，2004,1(2):148-161. DOI：10.1191/1740774504cn018oa.
[20]	ANTUNES P E, DE OLIVEIRA J F, ANTUNES M J. Risk-prediction for postoperative major morbidity in coronary surgery[J]. Eur J Cardiothorac Surg，2009,35(5):760-766;discussion 766-767. DOI：10.1016/j.ejcts.2008.10.046.
[21]	KALYONCUOGLU M, OZTURK S, SAHIN M. Does CHA₂DS₂-VASc score predict MACE in patients undergoing isolated coronary artery bypass grafting surgery?[J]. Braz J Cardiovasc Surg，2019,34(5):542-549. DOI：10.21470/1678-9741-2018-0323.

组别	例数	性别（男/女）	年龄（岁）	BMI 〔M（P₂₅，P₇₅），kg/m²〕	高血压〔例（%）〕	糖尿病〔例（%）〕	吸烟史〔例（%）〕	充血性心力衰竭〔例（%）〕
轻度病变组	276	212/64	61.99±10.97	24.2（22.2，26.2）	183（66.3）	85（30.8）	113（40.9）	55（20.0）
中度病变组	249	192/57	66.06±10.53	24.2（22.0，26.4）	175（70.3）	82（32.9）	102（41.0）	100（40.2）
重度病变组	105	84/21	65.94±11.39	24.4（22.8，26.4）	65（61.9）	37（35.2）	50（47.6）	61（58.1）
检验统计量值		0.472^a	10.710^b	0.899^c	2.505^a	0.742^a	1.201^a	55.253^a
P值		0.790	<0.001	0.638	0.286	0.690	0.549	<0.001
组别	外周血管疾病〔例（%）〕	心房颤动〔例（%）〕	TC 〔M（P₂₅，P₇₅），mmol/L〕	HDL-C 〔M（P₂₅，P₇₅），mmol/L〕	LDL-C 〔M（P₂₅，P₇₅），mmol/L〕	肌酐（μmol/L）	eGFR 〔mL·min^-1·（1.73m²）^-1〕
轻度病变组	215（77.9）	6（2.2）	4.61（4.14，5.67）	1.18（1.02，1.37）	2.92（2.41，3.74）	107.45±78.28	89.66±30.31
中度病变组	215（86.3）	9（3.6）	4.86（4.20，5.93）	1.20（1.03，1.37）	3.13（2.54，3.91）	113.61±79.18	83.23±29.44
重度病变组	87（82.9）	1（1.0）	5.01（4.00，5.88）	1.12（0.94，1.36）	3.11（2.42，3.85）	118.05±82.40	80.25±28.47
检验统计量值	0.278^a	2.390^a	2.874^c	2.489^c	2.442^c	0.805^b	5.084^b
P值	0.870	0.303	0.238	0.288	0.295	0.448	0.006
组别	血红蛋白（g/L）	LVEF （%）	MACEs 〔例（%）〕	死亡〔例（%）〕	非致死心肌梗死〔例（%）〕	SYNTAX评分（分）	CHA₂DS₂-VASc评分（分）
轻度病变组	130.65±16.48	50.03±7.96	26（9.4）	22（8.0）	4（1.4）	16.69±3.56	3.18±1.87
中度病变组	129.72±16.95	45.66±10.52	47（18.9）	37（14.9）	10（4.0）	26.72±2.64	4.33±1.98
重度病变组	127.43±17.21	42.67±12.09	23（21.9）	14（13.3）	9（8.6）	38.45±5.80	4.42±2.11
检验统计量值	1.392^b	25.552^b	20.781^a	6.438^a	11.125^a	1 386.604^b	28.512^b
P值	0.249	<0.001	<0.001	0.040	0.004	<0.001	<0.001

组别	例数	性别（男/女）	年龄（岁）	BMI 〔M（P₂₅，P₇₅），kg/m²〕	高血压〔例（%）〕	糖尿病〔例（%）〕	吸烟史〔例（%）〕	充血性心力衰竭〔例（%）〕
轻度病变组	276	212/64	61.99±10.97	24.2（22.2，26.2）	183（66.3）	85（30.8）	113（40.9）	55（20.0）
中度病变组	249	192/57	66.06±10.53	24.2（22.0，26.4）	175（70.3）	82（32.9）	102（41.0）	100（40.2）
重度病变组	105	84/21	65.94±11.39	24.4（22.8，26.4）	65（61.9）	37（35.2）	50（47.6）	61（58.1）
检验统计量值		0.472^a	10.710^b	0.899^c	2.505^a	0.742^a	1.201^a	55.253^a
P值		0.790	<0.001	0.638	0.286	0.690	0.549	<0.001
组别	外周血管疾病〔例（%）〕	心房颤动〔例（%）〕	TC 〔M（P₂₅，P₇₅），mmol/L〕	HDL-C 〔M（P₂₅，P₇₅），mmol/L〕	LDL-C 〔M（P₂₅，P₇₅），mmol/L〕	肌酐（μmol/L）	eGFR 〔mL·min^-1·（1.73m²）^-1〕
轻度病变组	215（77.9）	6（2.2）	4.61（4.14，5.67）	1.18（1.02，1.37）	2.92（2.41，3.74）	107.45±78.28	89.66±30.31
中度病变组	215（86.3）	9（3.6）	4.86（4.20，5.93）	1.20（1.03，1.37）	3.13（2.54，3.91）	113.61±79.18	83.23±29.44
重度病变组	87（82.9）	1（1.0）	5.01（4.00，5.88）	1.12（0.94，1.36）	3.11（2.42，3.85）	118.05±82.40	80.25±28.47
检验统计量值	0.278^a	2.390^a	2.874^c	2.489^c	2.442^c	0.805^b	5.084^b
P值	0.870	0.303	0.238	0.288	0.295	0.448	0.006
组别	血红蛋白（g/L）	LVEF （%）	MACEs 〔例（%）〕	死亡〔例（%）〕	非致死心肌梗死〔例（%）〕	SYNTAX评分（分）	CHA₂DS₂-VASc评分（分）
轻度病变组	130.65±16.48	50.03±7.96	26（9.4）	22（8.0）	4（1.4）	16.69±3.56	3.18±1.87
中度病变组	129.72±16.95	45.66±10.52	47（18.9）	37（14.9）	10（4.0）	26.72±2.64	4.33±1.98
重度病变组	127.43±17.21	42.67±12.09	23（21.9）	14（13.3）	9（8.6）	38.45±5.80	4.42±2.11
检验统计量值	1.392^b	25.552^b	20.781^a	6.438^a	11.125^a	1 386.604^b	28.512^b
P值	0.249	<0.001	<0.001	0.040	0.004	<0.001	<0.001

变量	β	SE	Wald χ²值	P值	OR（95%CI）
性别
男	0.415	0.238	3.026	0.082	1.514（0.949，2.416）
年龄	0.040	0.010	14.654	<0.001	1.040（1.019，1.062）
BMI	0.056	0.032	2.990	0.084	0.945（0.887，1.008）
高血压
有高血压	0.290	0.220	1.735	0.188	1.336（0.868，2.056）
糖尿病
有糖尿病	-0.219	0.219	2.761	0.097	0.694（0.452，1.068）
吸烟史
有吸烟史	0.113	0.218	0.268	0.605	1.119（0.730，1.715）
eGFR	-0.012	0.004	10.127	0.001	0.988（0.981，0.995）
LVEF	-0.037	0.008	19.200	<0.001	0.964（0.948，0.980）
CHA₂DS₂-VASc评分	0.210	0.052	16.061	<0.001	1.233（1.113，1.367）
SYNTAX评分	0.051	0.012	18.689	<0.001	1.053（1.028，1.077）

变量	β	SE	Wald χ²值	P值	OR（95%CI）
性别
男	0.415	0.238	3.026	0.082	1.514（0.949，2.416）
年龄	0.040	0.010	14.654	<0.001	1.040（1.019，1.062）
BMI	0.056	0.032	2.990	0.084	0.945（0.887，1.008）
高血压
有高血压	0.290	0.220	1.735	0.188	1.336（0.868，2.056）
糖尿病
有糖尿病	-0.219	0.219	2.761	0.097	0.694（0.452，1.068）
吸烟史
有吸烟史	0.113	0.218	0.268	0.605	1.119（0.730，1.715）
eGFR	-0.012	0.004	10.127	0.001	0.988（0.981，0.995）
LVEF	-0.037	0.008	19.200	<0.001	0.964（0.948，0.980）
CHA₂DS₂-VASc评分	0.210	0.052	16.061	<0.001	1.233（1.113，1.367）
SYNTAX评分	0.051	0.012	18.689	<0.001	1.053（1.028，1.077）

变量	β	SE	Wald χ²值	P值	OR（95%CI）
高血压
有高血压史	0.561	0.263	4.553	0.033	1.753（1.047，2.938）
LVEF	-0.039	0.011	13.629	<0.001	0.962（0.942，0.982）
CHA₂DS₂-VASc评分	0.191	0.063	9.187	0.002	1.210（1.070，1.369）
SYNTAX评分	0.028	0.013	4.626	<0.031	1.028（1.002，1.055）

The Predictive Value of CHA₂DS₂-VASc Score on Major Adverse Cardiovascular Events in Patients with Three Vessels or Left Main Diseases of Coronary Heart Disease

CHA₂DS₂-VASc卒中风险评分对冠心病三支血管或左主干病变患者主要不良心血管事件的预测价值研究

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 21

Related Articles 15

Recommended Articles

Metrics

Comments

变量	全因死亡			非致死性心肌梗死
变量	SHR	95%CI	P值	SHR	95%CI	P值
SYNTAX评分	0.969	（0.945，0.993）	0.012	1.029	（0.989，1.070）	0.158
CHA₂DS₂-VASc评分	1.301	（1.133，1.294）	<0.001	1.289	（1.014，1.640）	0.038

变量	AUC差值	SE	95%CI	Z值	P值
SYNTAX评分vs. CHA₂DS₂-VASc评分	0.019 1	0.035 1	（-0.050，0.088）	0.543	0.587
SYNTAX评分vs.联合应用SYNTAX评分和CHA₂DS₂-VASc评分	0.046 9	0.018 6	（0.010，0.083）	2.000	0.046
CHA₂DS₂-VASc评分vs.联合应用SYNTAX评分和CHA₂DS₂-VASc评分	0.065 9	0.019 3	（0.028，0.099）	2.021	0.043

[1]	YUAN Mingpei, LIN Yaowang, BEI Weijie, LIU Huadong, DONG Shaohong, SUN Xin. Feasibility of Retrograde Recanalization of Occluded Radial Artery via Distal Transradial Artery Approach: a Single-center Prospective Study [J]. Chinese General Practice, 2023, 26(27): 3373-3377.
[2]	CAI Gaojun, SHI Ganwei, LI Feng, LI Wenhua, YAN Yongmin, XUE Sheliang, XIAO Jianqiang, GU Jun, SONG Yanbin, ZHANG Liuyan, LU Wei, GONG Chun. How to Improve the Success Puncture Rate of Distal Transradial Artery Approach, "Winding Path to the Secluded": Summary of the Experience of More than 2 000 Cases [J]. Chinese General Practice, 2023, 26(27): 3361-3365.
[3]	LIU Minghao, WANG Pan, GAO Lijian, XU Shuqing, WANG Huanhuan, ZHAO Guangxian, CHEN Jue, QIAO Shubin, XU Bo, YUAN Jinqing. Feasibility, Safety and Timing of Secondary Percutaneous Coronary Intervention via Distal Transradial Artery Approach [J]. Chinese General Practice, 2023, 26(27): 3366-3372.
[4]	LAN Yonghao, KE Erqin, HAN Rui, MEI Yingchen, LIU Wei. Percutaneous Coronary Intervention via Distal Transradial Approach: Strengths, Weaknesses, Opportunities and Challenges [J]. Chinese General Practice, 2023, 26(27): 3355-3360.
[5]	GAO Yang, WANG Yunxia, ZHANG You, GAO Chuanyu. Lipid Goal Attainment Rate and Influencing Factors in 45-year-old or Younger Acute Coronary Syndrome Patients with an Ultra-high Risk of Atherosclerotic Cardiovascular Disease after Lipid-lowering Treatment [J]. Chinese General Practice, 2023, 26(27): 3383-3387.
[6]	CHEN Yan, LYU Zhibo, ZHAO Xin. Correlation of Discordance between Remnant Lipoprotein Cholesterol and Non-high-density Lipoprotein Cholesterol and Severity of Coronary Stenosis [J]. Chinese General Practice, 2023, 26(24): 3010-3015.
[7]	JIANG Qixia, ZHOU Jihong, CHEN Kesu, HONG Yanyan, PENG Qing, ZHAN Yingying, XIE Yijie, SUN Ying, WANG Zujing. Pressure Injuries among Adult Inpatients in 46 Tertiary Hospitals in China: Epidemiological Characteristics and Predictive Value of the Braden Scale [J]. Chinese General Practice, 2023, 26(18): 2195-2202.
[8]	CHEN Yijia, QI Shengxiang, DU Jinling, WANG Chenchen, ZHOU Hairong, YE Qing, QIN Zhenzhen, SU Jian, WU Ming, HONG Xin. Predictive Value of Cardiometabolic Index for Metabolically Obese Phenotype in Normal Weight Population [J]. Chinese General Practice, 2023, 26(14): 1716-1725.
[9]	CHEN Ying, WANG Zihan, XUE Chongxiang, TAO Shiyi, SUN Ziyi, HUANG Li. The Predictive Value of Ankle Brachial Index, Brachial-ankle Pulse Wave Velocity, Flow-mediated Dilation Combined with Apolipoprotein B to Apolipoprotein A-1 Ration on Coronary Heart Disease with Blood Stasis Syndrome in Middle-aged and Young Adults [J]. Chinese General Practice, 2023, 26(14): 1726-1732.
[10]	CHAI Yan, ZHAO Yuqing, GUO Xunan, WANG Dongying, BIAN Yunfei. Bioinformatics Analysis of the Role of Epicardial Adipose Tissue in Coronary Artery Disease [J]. Chinese General Practice, 2023, 26(08): 939-950.
[11]	Ke QIN, Tonglin LI, Shuai GONG, Meifang JIANG. Changes and Response Predictive Values of Serum miR-210 and miR-181a in Stable Chronic Obstructive Pulmonary Disease Patients Treated with Glucocorticoid Therapy [J]. Chinese General Practice, 2022, 25(24): 3013-3017.
[12]	Jingjing GUI, Aquan JIN, Yu WAN, Xuan ZHAO, Linjie ZHU, Yidong ZHAO, Jiaqi YAO, Liwen ZHANG, Zhiying HUANG. Value of Thromboelastography for Condition Assessment in Children with Mycoplasma Pneumoniae Pneumonia [J]. Chinese General Practice, 2022, 25(21): 2624-2628.
[13]	Yan LUO, Bingyi ZHAO, Yanmei SUN, Haishen TIAN, Yali LI, Yanshang ZHANG, Jian GAO, Zhiqiang CUI. Prenatal Diagnosis and Pregnancy Outcome Analysis of High-risk Fetuses Suggested by Noninvasive Prenatal Screening [J]. Chinese General Practice, 2022, 25(20): 2482-2488.
[14]	Xin BAO, Changhong LU, Yuan ZHAO, Xiaoli GUAN, Qianwen NIE, Wenxia LIANG, Jing ZHANG, Zhengyi ZHANG. Relationship of Triglyceride-glucose Index with Coronary and Carotid Atherosclerosis [J]. Chinese General Practice, 2022, 25(15): 1845-1849.
[15]	LI Hang, LIU Yiying, LIU Yao, LIN Jie, WAN Qin. Predictive Value of Hemoglobin Glycation Index for Hyperuricemia in Type 2 Diabetes [J]. Chinese General Practice, 2022, 25(06): 693-698.